Go Pro
→ DOJ Admits It In Court—Your Cash Can Be Seized Without Warning (From Priority Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$34.38
+0.8%		$24.54
$10.37
▼
$41.14
$3.83B-0.131.68 million shs298,064 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$9.50
-0.5%		$8.55
$4.30
▼
$9.73
$489.87M1.24342,108 shs182,245 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%+1.04%+49.43%+151.66%+234.31%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.00%+4.83%+7.18%+35.46%+89.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$34.38
+0.8%		$24.54
$10.37
▼
$41.14
$3.83B-0.131.68 million shs298,064 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$9.50
-0.5%		$8.55
$4.30
▼
$9.73
$489.87M1.24342,108 shs182,245 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%+1.04%+49.43%+151.66%+234.31%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.00%+4.83%+7.18%+35.46%+89.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$36.506.18% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
2.00
Hold$6.00-36.83% Downside

Current Analyst Ratings Breakdown

Latest AMLX and PBYI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$55.00 ➝ $57.00
8/21/2026
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$40.00 ➝ $55.00
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$28.00 ➝ $52.00
8/18/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$30.00 ➝ $42.00
8/18/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$34.00 ➝ $55.00
8/17/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/17/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$24.00 ➝ $30.00
8/7/2026
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
8/7/2026
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$5.00 ➝ $6.00
8/5/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M43.84N/AN/A$2.78 per share12.37
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$231.24M2.12$0.83 per share11.45$2.59 per share3.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.43N/AN/AN/AN/A-52.92%-48.53%11/5/2026 (Estimated)
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$31.11M$0.5218.2567.84N/A11.50%20.76%13.22%11/5/2026 (Estimated)

Latest AMLX and PBYI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3609-$0.39-$0.0291-$0.39N/AN/A
8/6/2026Q2 2026
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.04$0.19+$0.15$0.16$53.00 million$56.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
12.12
12.12
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/A
2.91
2.64

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10.90%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
22.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
200111.42 million99.28 millionOptionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20051.62 million40.16 millionOptionable

Recent News About These Companies

Bank of New York Mellon Corp Takes $2.93 Million Position in Puma Biotechnology, Inc. $PBYI
September 7 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-takes-293-million-position-in-puma-biotechnology-inc-pbyi-2026-09-07/
FY2026 EPS Forecast for Puma Biotechnology Lifted by Analyst
September 5 at 1:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003729
220,316 Shares in Puma Biotechnology, Inc. $PBYI Purchased by Empowered Funds LLC
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-220316-shares-in-puma-biotechnology-inc-pbyi-purchased-by-empowered-funds-llc-2026-09-04/
Zacks Research Brokers Decrease Earnings Estimates for PBYI
September 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31001690
Zacks Research Has Positive Outlook of PBYI FY2026 Earnings
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-zacks-research-has-positive-outlook-of-pbyi-fy2026-earnings-2026-09-03/
Puma Biotechnology (NASDAQ:PBYI) Sets New 12-Month High - Still a Buy?
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-puma-biotechnology-nasdaq-pbyi-sets-new-12-month-high-still-a-buy-2026-09-02/
Q3 EPS Forecast for Puma Biotechnology Lowered by Analyst
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-q3-eps-forecast-for-puma-biotechnology-lowered-by-analyst-2026-09-02/
3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc.
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-3804736-shares-in-puma-biotechnology-inc-pbyi-bought-by-blackrock-inc-2026-09-02/
Connor Clark & Lunn Investment Management Ltd. Acquires New Holdings in Puma Biotechnology, Inc. $PBYI
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-connor-clark-lunn-investment-management-ltd-acquires-new-holdings-in-puma-biotechnology-inc-pbyi-2026-08-28/
Globeflex Capital L P Invests $3.10 Million in Puma Biotechnology, Inc. $PBYI
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-globeflex-capital-l-p-invests-310-million-in-puma-biotechnology-inc-pbyi-2026-08-24/
Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/puma-biotechnology-nasdaqpbyi-upgraded-at-wall-street-zen-2026-08-15/
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
August 12, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2973438/is-puma-biotechnology-pbyi-a-great-value-stock-right-now?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_2-2973438
Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934401-puma-biotechnology-inc-2026-q2-results-earnings-call-presentation
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971131/pbyi-q2-earnings-sales-beat-estimates-2026-guidance-raised?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2971131
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933200-puma-biotechnology-inc-pbyi-q2-2026-earnings-call-transcript
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970603/puma-biotech-pbyi-q2-earnings-and-revenues-top-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2970603
Puma Biotechnology Reports Second Quarter 2026 Financial Results
August 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260806108241/en/puma-biotechnology-reports-second-quarter-2026-financial-results/
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline
July 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2964563/earnings-preview-puma-biotech-pbyi-q2-earnings-expected-to-decline?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_9-2964563
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
July 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/puma-biotechnology-host-conference-call-201000109.html
Douglas Hunt Sells 8,460 Shares of Puma Biotechnology (NASDAQ:PBYI) Stock
July 9, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pbyi-insider-buying-and-selling-2026-07-09/
Puma Biotechnology Shareholders Back Governance, Reject Warrant Extension
June 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/puma-biotechnology-shareholders-back-governance-reject-warrant-extension?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$34.38 +0.28 (+0.81%)
As of 12:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$9.50 -0.05 (-0.54%)
As of 12:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas